1. bookVolume 22 (2014): Issue 1 (March 2014)
Journal Details
License
Format
Journal
eISSN
2284-5623
ISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Mathematical model to predict methotrexate elimination in children with acute lymphoblastic leukemia

Journal Details
License
Format
Journal
eISSN
2284-5623
ISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction: Methotrexate, a structural analogue to the folic acid, is one of the most frequently used antimetabolites in pediatric oncologic pathology. Its mode of action and toxic effects are now well known. Material

and method: Our study aimed to describe the quantitation of the drug in serum of 40 children with acute lymphatic leukemia receiving high doses of methotrexate and to predict serum methotrexate levels at 96 hours, based on 48 h, 72h levels and on alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea, and creatinine serum levels. The above mentioned parameters were analyzed by sampling serum levels at 48h, 72h and 96 hours after methotrexate administration and a logical regression model being projected upon obtained results. Results and conclusions: methotrexate serum level at 96 hours does not depend on either AST, ALT, urea, creatinine levels or on the methotrexate level determined at 48 hours, it only depends on the methotrexate serum level at 72 hours.

Keywords

Cuvinte cheie

1. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010;24(2):309-19 DOI: 10.1038/ leu.2009.25810.1038/leu.2009.258Search in Google Scholar

2. Kampen KR. The discovery and early understanding of leukemia. Leuk Res. 2012;36(1):6-13. DOI: 10.1016/j. leukres.2011.09.028Search in Google Scholar

3. Mantadakis E, Cole PD, Kamen BA. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy. 2005;25(5):748-55. DOI: 10.1592/phco.25.5.748.6358410.1592/phco.25.5.748.63584Search in Google Scholar

4. Sterba J, Valík D, Bajciová V, Kadlecová V, Gregorová V, Mendelová D. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma. 2005;52(6):456-63.Search in Google Scholar

5. Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L et al.: Long-term results of Dana- Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24(2):320-34. DOI: 10.1038/leu.2009.25310.1038/leu.2009.253Search in Google Scholar

6. Veerman AJ, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14(3):911-8.10.1200/JCO.1996.14.3.911Search in Google Scholar

7. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children’s Oncology Group. Leukemia. 2010;24(2):355-70. DOI: 10.1038/leu.2009.26110.1038/leu.2009.261Search in Google Scholar

8. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371-82. DOI: 10.1038/leu.2009.25210.1038/leu.2009.252Search in Google Scholar

9. Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118(2):243-51. DOI: 10.1182/ blood-2010-12-32290910.1182/blood-2010-12-322909Search in Google Scholar

10. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer S, Steuber CP, Camitta B. Intensification with intermediate- dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol. 2000;18(6):1285-94.10.1200/JCO.2000.18.6.1285Search in Google Scholar

11. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):345-54. DOI: 10.1038/leu.2009.25110.1038/leu.2009.251Search in Google Scholar

12. Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2010;24(2):406-18. DOI: 10.1038/leu.2009.25610.1038/leu.2009.256Search in Google Scholar

13. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med. 1998;338(8):499-505. DOI: 10.1056/NEJM19980219338080310.1056/NEJM199802193380803Search in Google Scholar

14. Mahoney DH, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower- risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III Trial. J Clin Oncol. 1998;16(1):246-54.10.1200/JCO.1998.16.1.246Search in Google Scholar

15. Camitta B, Mahoney D, Leventhat B, Lauer SJ, Shuster JJ, Adair S, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1994;12(7):1383-9.10.1200/JCO.1994.12.7.1383Search in Google Scholar

16. Camitta B, Leventhal B, Lauer S, Shuster JJ, Adair S, Casper J, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol. 1989;7(10):1539-44.10.1200/JCO.1989.7.10.1539Search in Google Scholar

17. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-84. DOI: 10.1038/leu.2009.25710.1038/leu.2009.257Search in Google Scholar

18. Ahmed YA, Hasan Y. Prevention and Management of High Dose Methotrexate Toxicity. J Cancer Sci Ther 2013;5(3):106-12. DOI: 10.4172/1948-5956.100019310.4172/1948-5956.1000193Search in Google Scholar

19. Le Guellec C, Blasco H, Benz J, Hulin A. Therapeutic drug monitoring of methotrexate after its administrations in high-dose protocols. Therapie. 2010;65(3):163-9. DOI: 10.2515/therapie/201001610.2515/therapie/2010016Search in Google Scholar

20. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30(6):570-81. DOI: 10.1016/j.semnephrol. 2010.09.005Search in Google Scholar

21. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman P, et al. Clinical pharmacodynamics of high-dose methotrexate in childhood acute lymphocytic leukemia. Identification of a relation between concentration and effect. New Engl J Med. 1986;314(8):471-7. DOI: 10.1056/NEJM19860220314080310.1056/NEJM198602203140803Search in Google Scholar

22. Panetta JC, Wall A, Pui CH, Relling MV, Evans WE. Methotrexate Intracellular Dispositionin Acute Lymphoblastic Leukemia.A Mathematical model of γ-Glutamyl Hydrolase Activity. Clin Cancer Res. 2002;8(7):2423-9.Search in Google Scholar

23. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchinson R et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874-83. DOI: 10.1182/ blood-2010-06-29261510.1182/blood-2010-06-292615Search in Google Scholar

24. Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Oncologist. 1996;1(4):223-6.10.1634/theoncologist.1-4-223Search in Google Scholar

25. Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 1996;21(5-6):359-68. DOI: 10.3109/1042819960909343310.3109/10428199609093433Search in Google Scholar

26. Gorlick R, Goker E, Trippett T, Watham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. New Engl J Med. 1996;335(14):1041-8. DOI: 10.1056/ NEJM19961003335140810.1056/NEJM199610033351408Search in Google Scholar

27. Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15(4):1560-6.10.1200/JCO.1997.15.4.1560Search in Google Scholar

28. Moe PJ, Holen A.: High-dose methotrexate in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 2000;17(8):615-22. DOI: 10.1080/0888001005021132110.1080/08880010050211321Search in Google Scholar

29. Maiquma T, Hayashi Y, Ueshima S, Kaji M, Eqawa T, Chayama T, et al. Relationship between oral mucositis and high-dose methotrexate in pediatric acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 2008;46(11):584-90. DOI: 10.5414/CPP4658410.5414/CPP46584Search in Google Scholar

30. Xu WQ, Tang YM, Fanq CQ, Song H, Shi SW, Yang SL, et al. Study on elimination delay in high-dose methotrexate in children with acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2005;26(1):15-8.Search in Google Scholar

31. Isoda T, Ito S, Kajiwara M, Nagasawa M. Successful high-dose methotrexate therapy in a patient with acute lymphoblastic leukemia who developed acute renal failure during initial treatment. Pediatr Int. 2007;49(6):1018-9. DOI: 10.1111/j.1442-200X.2007.02461.x10.1111/j.1442-200X.2007.02461.xSearch in Google Scholar

32. Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy. 2005:25(9):1271-6. DOI: 10.1592/phco.2005.25.9.127110.1592/phco.2005.25.9.1271Search in Google Scholar

33. Joannon P, Oviedo I, Campbell M, Tordecilla J. High dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer. 2004;43(1):17-22. DOI: 10.1002/ pbc.2003210.1002/pbc.20032Search in Google Scholar

34. Borsi JD, Moe PJ. Systemic Clearance of Methotrexate in the Prognosis of Acute Lymphoblastic Leukemia in Children. Cancer. 1987;60(12):3020-4. DO I:2/1097-0142(19871215)60:12<3020::AID-CNCR2820601227> 3.0.CO;2-010.1002/1097-0142(19871215)60:12<3020::AID-CNCR2820601227>3.0.CO;2-0Search in Google Scholar

35. Hein DW, Doll MA. Accuracy of various NAT 2 SNP genotyping panelsto infer rapid, intermediateand slow acetylator phenotypes. Pharmacogenomics. 2012;13(1):31-41. DOI: 10.2217/pgs.11.122 10.2217/pgs.11.122Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo